Syros Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for the treatment of cancer and other serious diseases through the manipulation of gene regulation
The company leverages its proprietary technology platform to identify and develop small molecules that target specific genes and cellular pathways, aiming to disrupt the disease process at the molecular level. Syros is dedicated to advancing its pipeline of product candidates, which are designed to selectively modulate gene expression and provide new treatment options for patients with unmet medical needs. Through its research and development efforts, Syros aims to improve patient outcomes and ultimately transform the landscape of disease management.
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, impacting future trial plans.
Syros Pharmaceuticals announces discontinuing enrollment in the SELECT-AML-1 Phase 2 trial due to the low probability of demonstrating superiority. The trial evaluated tamibarotene with venetoclax and azacitidine in acute myeloid leukemia patients.
U.S. stocks traded lower toward the end of trading, with the S&P 500 falling around 0.4% on Tuesday. The Dow traded down 0.46% to 38,713.72 while the NASDAQ fell 0.24% to 16,215.32. The S&P 500 also fell, dropping, 0.39% to 5,182.36.
Shares of Tilray Brands, Inc. (NASDAQTLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free
